Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Operating Leases (2018 - 2026)

Cytosorbents filings provide 8 years of Operating Leases readings, the most recent being $11.9 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 4.35% to $11.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 million, a 4.35% decrease, with the full-year FY2025 number at $11.9 million, down 4.35% from a year prior.
  • Operating Leases hit $11.9 million in Q4 2025 for Cytosorbents, down from $12.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $13.5 million in Q2 2022 to a low of $461064.0 in Q1 2021.
  • Median Operating Leases over the past 5 years was $13.0 million (2022), compared with a mean of $12.2 million.
  • Biggest five-year swings in Operating Leases: fell 12.56% in 2021 and later surged 2756.95% in 2022.
  • Cytosorbents' Operating Leases stood at $13.3 million in 2021, then dropped by 0.82% to $13.1 million in 2022, then decreased by 1.87% to $12.9 million in 2023, then dropped by 3.51% to $12.4 million in 2024, then decreased by 4.35% to $11.9 million in 2025.
  • The last three reported values for Operating Leases were $11.9 million (Q4 2025), $12.1 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.